Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neoplasms 9 Carcinoma, Non-Small-Cell Lung 9 Carcinoma, Renal Cell 4 Carcinoma, Hepatocellular 4 Breast Neoplasms 3 Stomach Neoplasms 2 Solid Tumors 2 Mesothelioma, Malignant 2 Melanoma 2 Carcinoma 2 Adult Solid Neoplasm 2 Triple Negative Breast Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Solitary Fibrous Tumor, Pleural 1 Solid Neoplasm 1 Seminoma 1 Sarcoma, Clear Cell 1 Sarcoma, Alveolar Soft Part 1 Sarcoma 1 Renal Insufficiency 1 Prostatic Neoplasms 1 Paraproteinemias 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Osteolysis 1 Neoplasm Metastasis 1 Multiple Myeloma 1 Malignant Solid Tumour 1 Liver Neoplasms 1 Hypercalcemia 1

Interventions

Doxorubicin 142 Ifosfamide 85 Radiotherapy 82 Cyclophosphamide 72 Gemcitabine 63 Filgrastim 54 pembrolizumab 43 pazopanib 40 Etoposide 39 Docetaxel 39 Vincristine 37 Trabectedin 37 Cisplatin 35 Nivolumab 32 Magnetic Resonance Spectroscopy 26 Irinotecan 26 Carboplatin 25 Temozolomide 23 Surgical Procedures, Operative 23 Radiation 22 Ipilimumab 22 Bevacizumab 20 Blood Specimen Collection 19 Granulocyte Colony-Stimulating Factor 18 Biopsy 18 eribulin 17 Sirolimus 17 Mesna 17 Melphalan 17 Dactinomycin 17

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Sarcoma × ARQ 197 × Clear all

NCT01468922 2022-07-01

Pazopanib and ARQ 197 for Advanced Solid Tumors

National Institutes of Health Clinical Center (CC)

Phase 1 Completed

32 enrolled 21 charts

Neoplasms, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡